Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Prevention and risk

Reviewed as evidence on: Shingles (zoster) vaccination and dementia onset 5 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Plain-language summary

Neurotropic herpesviruses may be implicated in the development of dementia 1-5 . Moreover, vaccines may have important off-target immunological effects 6-9 . Here we aim to determine the effect of live-attenuated herpes zoster vaccination on the occurrence of dementia diagnoses. To provide causal as opposed to correlational evidence, we take advantage of the fact that, in Wales, eligibility for the zoster vaccine was determined on the basis of an individual's exact date of birth. Those born before 2 September 1933 were ineligible and remained ineligible for life, whereas those born on or after 2 September 1933 were eligible for at least 1 year to receive the vaccine. Using large-scale electronic health record data, we first show that the percentage of adults who received the vaccine increased from 0.01% among patients who were merely 1 week too old to be eligible, to 47.2% among those who were just 1 week younger. Apart from this large difference in the probability of ever receiving the zoster vaccine, individuals born just 1 week before 2 September 1933 are unlikely to differ systematically from those born 1 week later. Using these comparison groups in a regression discontinuity design, we show that receiving the zoster vaccine reduced the probability of a new dementia diagnosis over a follow-up period of 7 years by 3.5 percentage points (95% confidence interval (CI) = 0.6-7.1, P = 0.019), corresponding to a 20.0% (95% CI = 6.5-33.4) relative reduction. This protective effect was stronger among women than men. We successfully confirm our findings in a different population (England and Wales's combined population), with a different type of data (death certificates) and using an outcome (deaths with dementia as primary cause) that is closely related to dementia, but less reliant on a timely diagnosis of dementia by the healthcare system 10 . Through the use of a unique natural experiment, this study provides evidence of a dementia-preventing or dementia-delaying effect from zoster vaccination that is less vulnerable to confounding and bias than the existing associational evidence.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. In this Welsh natural experiment, receiving the herpes zoster vaccine reduced the probability of a new dementia diagnosis over 7 years by 3.5 percentage points. Its stated limit: Wide confidence interval on the main estimate; studied the older live attenuated vaccine (Zostavax) rather than the current recombinant Shingrix; mechanism unknown; single-country cohort born in 1933.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Eyting, M., Xie, M., Michalik, F., Heß, S., Chung, S., & Geldsetzer, P. (2025). A natural experiment on the effect of herpes zoster vaccination on dementia (Wales). Nature. https://doi.org/10.1038/s41586-025-08800-x

Vancouver

Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia (Wales). Nature. 2025. doi:10.1038/s41586-025-08800-x. PMID: 40175543.

BibTeX

@article{eyting2025-40175543,
  author  = {Eyting, M. and Xie, M. and Michalik, F. and Heß, S. and Chung, S. and Geldsetzer, P.},
  title   = {{A natural experiment on the effect of herpes zoster vaccination on dementia (Wales)}},
  journal = {Nature},
  year    = {2025},
  doi     = {10.1038/s41586-025-08800-x},
  pmid    = {40175543},
  url     = {https://doi.org/10.1038/s41586-025-08800-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this Welsh natural experiment, receiving the herpes zoster vaccine reduced the probability of a new dementia diagnosis over 7 years by 3.5 percentage points. The findings were confirmed in a different population using death certificates, but this is observational evidence and not a randomized trial.

Study details

Limitations

Wide confidence interval on the main estimate; studied the older live attenuated vaccine (Zostavax) rather than the current recombinant Shingrix; mechanism unknown; single-country cohort born in 1933.

How this study scored 74/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 3 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 73 of the 98 points it could be judged on, which is 74 of 100. Total 74 of 100.73 of the 98 points we could judge = 74 of 100

Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 73 of the 98 points we could judge it on, which is 74 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature)
Journal's citation record 4 / 4 Nature: journal h-index 1,841 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 240 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 80.0 citations a year over 3 year(s) since 2025
Impact for its field and year 6 / 6 Cited 137.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 13 other studies in this library
Still being cited 4 / 4 Cited 236 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Pascal Geldsetzer: h-index 48 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40175543)
Free to read — / 2 Access not recorded — left out of this score
Points 73 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 73 of the 98 points we could judge it on is 74 out of 100.
Total 74 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Prevention and risk from nearby years

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →